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persistent asthma in Spain is going to represent a savings of 11€
millions in the Spanish National Pharmaceutical budget in the
next 5 years.
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OBJECTIVES: Omalizumab is a monoclonal antibody indicated
for treatment of severe persistent allergic asthma inadequately
controlled despite an optimal controller therapy. The purpose of
this study is to determine a cost-effectiveness analysis of omali-
zumab vs ST in the treatment of severe asthma in Mexico.
METHODS: A cost-effectiveness analysis was performed based
on a six-state Markov model. The transition probabilities and the
response rate were obtained from a meta-analysis. The pattern of
resource use was derived from the Second Mexican Consensus of
Asthma (steps 4 and 5). Unit costs of resources and medications
were obtained from medical care in IMSS 2004, and were trans-
formed to current prices using inﬂation rates. The cost of oma-
lizumab was provided by the laboratory. The time horizon was
one year. A discount rate was not required. The model was
calibrated. The effectiveness rate was the number of days free
from exacerbations. A one-way and two-way probabilistic sen-
sitivity analysis was used using a Tornado chart. A stochastic
optimization analysis was performed with 500 runs involving
100,000 Monte Carlo iterations; the budget and percent use of
omalizumab were the model restrictions. Maximization of incre-
mental net beneﬁts was obtained with the model. RESULTS: The
expected cost per patient was $14,940 USD ($502) with oma-
lizumab, while this ﬁgure was $6,144 USD ($207) for ST. The
expected effectiveness was 333 (3) and 306 (6) days without
exacerbation/year, respectively. The stochastic optimization
maximized the net incremental beneﬁts with a ratio of 42% for
omalizumab, and 58% for the standard therapy. The sensitivity
analysis was robust in the conclusions of the basic study. CON-
CLUSION: Omalizumab is a cost-effective therapy in the
management of patients with severe asthma. The ratio for oma-
lizumab acquisition with stochastic optimization was 42%.
PAA5
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OBJECTIVES: To analyze cost-effectiveness of budesonid/
formoterol versus typical practice for treating asthma in Russian
health care system. METHODS: Open, randomized, compara-
tive trial was carried out in 16 cities of Russia. 300 outpatients
were observed during 6 months. A total of 150 from them
were prescribed budesonid/formoterol, 150 continued anti-
inﬂammatory therapy prescribed earlier (typical practice of treat-
ing patients). IN all, 103 patients from them received inhaled
corticosteroids 800–1600 mcg as monotherapy, 21 patient
received inhaled corticosteroids in a combination with long-
acting 2-agonists and 26 patient received cromons. The degree of
restriction of physical activity, frequency of day time and night
attacks were estimated on a scale in 5 points (0-absence of the
infringements, 2–4-moderate and heavy infringements). Applica-
tion of udesonid/formoterol has shown the best results by all
criteria of clinical efﬁciency. RESULTS: The increase of FEV1 by
the end of research (20% on a median) was signiﬁcantly greater
in group of abudesonid/formoterol than in control group (11%).
Cost of treatment (cost of drugs and physician visits) was some-
what higher in budesonid/formoterol group. Average cost-
effectiveness ratio showed that the cost per % increase of FEV1in
group of budesonid/formoterol (484,08 rubles for the 1 month,
1742.68 rubles for 6 months) was lower than in group of com-
parison (1131.56 rubles and 2468.86 rubles). Cost per patient
with absence of moderate or heavy infringements on all used
scales at the end of study also was lower in the ﬁrst group
(9220.54 rubles for the 1 month; 44,684.15 rubles for 6 months)
than in the second group (11,911.13 rubles, 59,037.78 rubles).
CONCLUSION: Budesonid/formoterol is cost-effective in treat-
ment of bronchial asthma.
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OBJECTIVES: A large scale database analysis was undertaken
comparing resource use in UK primary care patients receiving
inhaled steroids via MDI and BOI. The aim was to compare
resource use over a two-year period of patients receiving inhaled
beclometasone via MDI, with patients utilising BOI.
METHODS: Data was extracted from Din-Link patient-level
databases to compare resource utilisation over 24 months in
patients receiving BOI with those on standard MDI. Entry crite-
ria were: 1) Diagnosis of asthma; 2) Receiving beclometasone via
MDI; and 3) No other preventer medication. Index event was
change to a different MDI or BOI. Key measures included annua-
lised average costs of: i) Primary care consultation for asthma; ii)
Anti-asthma prescriptions; iii) Spacer devices; and iv) Hospital
referral and admissions for asthma. RESULTS: Primary care
medication costs for child patients were 108.62 (BAI) versus
77.23(MDI) and for adults were 79.35 (BAI) versus 92.76
(MDI). Non-medication resource use for child patients over the
period was: GP consultation (63.00 BAI vs 102.68 MDI);
outpatient attendance (18.43 BAI vs 22.62 MDI); hospital
admissions (0.00 BAI vs 15.46 MDI). Non-medication
resource use for adult patients was: GP consultation (82.75
BAI vs 114.20 MDI); outpatient attendance (10.75 BAI vs
12.30 MDI); hospital admissions (28.35 BAI vs 21.39
MDI). Total asthma costs over the two year period for BAI
patients were 190.05 (children) and 201.20 (adults). Com-
parative ﬁgures for MDI patients were 217.99 (children) and
240.56 (adults). CONCLUSION: The additional acquisition
cost associated with BOI appears to be offset by enhanced clinical
effectiveness. A trend in cost effectiveness emerged in favour of
BOI versus the equivalent MDI for both children and adults.
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A PHARMACOECONOMIC EVALUATION OF SUBLINGUAL
IMMUNOTHERAPY COMPAREDTO SUBCUTANEOUS
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OBJECTIVES: For patients with grass pollen induced rhinocon-
junctivitis where immunotherapy is appropriate there are cur-
rently two medically approved treatment alternatives available in
Finland and Norway: Subcutaneous Immunotherapy (SCIT) and
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Sublingual Immunotherapy (SLIT). Both contain the allergen
extract from timothy grass (Phleum pratense). The objective of
this analysis was to perform a pharmacoeconomic evaluation
of SLIT with a grass allergy tablet compared to SCIT in both
the Norwegian and Finnish markets. METHODS: A cost-
minimisation approach was deemed appropriate for this evalu-
ation, based on assessments of the alternative’s pharmacokinetic
proﬁles, potential mechanisms of actions and an indirect com-
parison of results from clinical trials. SLIT was judged to
provide at least comparable clinical outcomes to those of SCIT.
Total costs from a societal perspective related to the therapies
were calculated based on national data on resource use and unit
costs. Estimates of resource use were based on guidelines, the
literature and interviews with national clinical specialists.
Resources included the quantities used of the chosen immuno-
therapy, the number of physician visits related to administration
and follow up of the chosen therapy, patient travel and resources
lost due to absence from work in connection with receiving the
therapy. Unit costs were based on national tariffs and wage
statistics. RESULTS: The expected savings in total cost of treat-
ment with SLIT compared to SCIT are approximately 1160 €
and 900 € in Norway and Finland respectively. Alternative sce-
narios and one-way sensitivity analyses indicate the robustness
of the results. CONCLUSION: The result of this cost-
minimisation analysis indicates that for patients with grass
pollen induced rhinoconjunctivitis where immunotherapy is
appropriate, SLIT with a grass allergy tablet is a cost-saving
alternative to SCIT from a societal perspective, both in Norway
and in Finland.
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COST OF REFRACTORY SEVERE PERSISTENT ASTHMA IN
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OBJECTIVES: Asthma patients with severe persistent disease
(GINA Step 4) have the greatest medical need among the asth-
matic population but also consume the highest economic costs.
In our study we have selected severe persistent asthma patients
who have not responded to high-dose antiasthmatic drugs
(inhaled and oral corticosteroids, long-LABA, antileukotrienes
and theophylline). METHODS: In a retrospective setting we
have collected direct and indirect costs for 51 patients (32
women and 19 men) over the period of one year with refractory
asthma in four clinical centres during August to November
2006. RESULTS: The average time from diagnosis was 17.5
years. Two thirds of patients were fully disabled and in rest of
patients working absence was more than 90 days per year.
There was high occurrence of concomitant diagnoses—
hypertension in 37%, osteoporosis in 33% and gastropathy in
31% due to high doses of oral steroids. The mean length of
hospitalization was 11.8 days per year in standard ward and 2.6
days in critical care. Emergency department was visited 8.1
times per year and outpatient departments more than 20
times during the analysed time period. Total direct medical
costs were 4756 EUR/year. Expenditure for hospitalizations was
2320 EUR, outpatient care 374 EUR and emergency care 59
EUR. The cost of asthma medication was 1484 EUR and 226
EUR for other medication. Indirect costs (social and sickness
beneﬁts, productivity loss) were 7262 EUR per year. CONCLU-
SION: The annual total direct plus indirect costs of one patient
with refractory severe persistent asthma were 12018 EUR.
Based on this results there are unmet medical and economic
needs in therapy of this subset of asthma patients in Czech
Republic.
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OBJECTIVES: Compare risk-adjusted costs and patient out-
comes measured by hospitalizations and emergency room visits
in mild persistent asthma patients initiating regular use of inhaled
corticosteroids (ICS), ICS and long acting b2-agonists (LABA), or
leukotriene modiﬁers (LM). METHODS: Study patients, selected
from a privately insured claims database (1999–2005), had at
least one asthma diagnosis; no diagnosis of COPD; mild persis-
tent asthma as deﬁned by the 2005 HEDIS, Leidy’s reliever and
oral steroid methods, and the 2004 GINA guidelines; and initi-
ated regular use of ICS, ICS + LABA or LM. Chi-squared tests
were used for descriptive pairwise comparisons of patient out-
comes. Generalized linear models with log link and gamma dis-
tribution adjusting for patient characteristics were used for
comparisons of total and asthma-related direct costs in the
12-months after the ﬁrst regular study controller use. RESULTS:
The ﬁnal sample included 319 patients with regular use of ICS,
414 patients with ICS + LABA, and 550 patients with LM. There
were no signiﬁcant differences in patient outcomes, as measured
by hospitalizations and emergency room visits (all-cause as well
as asthma-speciﬁc) among the three cohorts. Total risk-adjusted
direct costs were signiﬁcantly lower with ICS and LM compared
with ICS + LABA (ICS: $4305, P = 0.0158 compared with
ICS + LABA; ICS + LABA: $4997, P < 0.0857 compared with
LM; LM: $4562) and not signiﬁcantly different between ICS and
LM. Asthma-related risk-adjusted direct costs were the lowest
with ICS compared with both ICS + LABA and LM (ICS: $782,
P < 0.01 compared with ICS + LABA, P < 0.01 compared with
LM; ICS + LABA: $1126, P < 0.01 compared with LM; LM:
$871). CONCLUSION: Regular ICS use in mild persistent
asthma was associated with lower total direct costs compared
with ICS + LABA and the lowest asthma-related direct costs
compared with ICS + LABA or LM, without any corresponding
difference in patient outcomes.
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ADULT ASTHMA:A COHORT ANALYSIS OF USE AND COST
OF HOSPITAL AND EMERGENCY DEPARTMENT CARE BY
LOCATION OF RESIDENCE OVERTWELVE MONTHS
O’Brien JA, Duran PA, Caro JJ
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OBJECTIVES: As asthma rates increase, questions about the
relationship to residential location have been raised in many
countries. Thus, inpatient and emergency department (ED) care
for adult (age > = 17 years) asthmatics and related costs were
examined by residential location for one year. METHODS: Using
2001–02 Massachusetts data, patients treated for asthma (ICD-9
principal diagnosis code: 493.00–493.92) were identiﬁed. An
encounter proﬁle was established for each patient starting with
the ﬁrst asthma-related stay/visit (index encounter) at any hospi-
tal or ED in 2001, and included all subsequent inpatient and ED
care for asthma within twelve months. Using zip codes, patients
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